Live Wire Reporter

Pheochromocytoma Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products

Pheochromocytoma Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products

March 10
04:40 2023
Pheochromocytoma Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products

DelveInsight’s, “Pheochromocytoma Pipeline Insight, 2023,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Pheochromocytoma pipeline landscape. It covers the Pheochromocytoma pipeline drug profiles, including Pheochromocytoma clinical trials and nonclinical stage products. It also covers the Pheochromocytoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Pheochromocytoma Emerging drugs, the Pheochromocytoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Pheochromocytoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Pheochromocytoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Pheochromocytoma clinical trials studies, Pheochromocytoma NDA approvals (if any), and product development activities comprising the technology, Pheochromocytoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Pheochromocytoma Pipeline Report

 

  • DelveInsight’s Pheochromocytoma Pipeline analysis depicts a robust space with 8+ active players working to develop 8+ pipeline treatment therapies.

 

  • The leading Pheochromocytoma Companies include Pfizer, Exelixis, Ipsen, Genentech, Astex Pharmaceuticals, Advanced Accelerator Applications, and others.

 

  • Promising Pheochromocytoma Pipeline Therapies include 123I-mIBG (meta-iodobenzylguanidine), Ultratrace Iobenguane (MIBG) I 131, Sunitinib, temsirolimus, vinorelbine ditartrate, isolated perfusion, melphalan, Indium-111 pentetreotide, and others.

 

  • The Pheochromocytoma companies and academics are working to assess challenges and seek opportunities that could influence Pheochromocytoma R&D. The Pheochromocytoma pipeline therapies under development are focused on novel approaches to treat/improve Pheochromocytoma.

 

Request a sample and discover the recent breakthroughs happening in the Pheochromocytoma Pipeline landscape @ Pheochromocytoma Pipeline Outlook Report

 

Pheochromocytoma Overview

Pheochromocytoma is a rare tumor that usually starts in the cells of one of your adrenal glands. It results in the release of too much epinephrine and norepinephrine, hormones that control heart rate, metabolism, and blood pressure. Pheochromocytoma may occur as a single tumor or as more than one growth. It usually develops in the center (medulla) of one or both adrenal glands. Symptoms associated with pheochromocytomas include high blood pressure (hypertension), headaches, excessive sweating, and/or heart palpitations. In approximately 25 to 35 percent of cases, pheochromocytomas may be inherited as an autosomal dominant trait.

 

Pheochromocytoma Emerging Drugs Profile

 

  • Sunitinib: Pfizer

Sunitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. Sunitinib is approved in first-line treatment for patients with advanced renal cell carcinoma (RCC) and for the treatment of patients with gastrointestinal stromal tumors (GIST) after disease progression or intolerance to imatinib mesylate therapy. The drug is in Phase II clinical studies for the treatment of Pheochromocytoma.

 

  • Guadecitabine: Astex Pharmaceuticals

Guadecitabine is a next-generation DNA hypomethylating agent. Guadecitabine is rationally designed to be resistant to degradation by cytidine deaminase, prolonging the exposure of tumor cells to the active metabolite, decitabine, thus ensuring greater uptake of decitabine into the DNA of rapidly dividing cancer cells. Guadecitabine-mediated inhibition of DNA methylation upregulates tumor-associated antigens and may sensitize tumor cells to other anticancer agents, including immunotherapeutics, as well as resensitize resistant cancer cells to chemotherapeutics. The drug is in Phase II clinical evaluation for the treatment of Pheochromocytoma.

 

For further information, refer to the detailed Pheochromocytoma Drugs Launch, Pheochromocytoma Developmental Activities, and Pheochromocytoma News, click here for Pheochromocytoma Ongoing Clinical Trial Analysis

 

Pheochromocytoma Pipeline Therapeutics Assessment

There are approx. 8+ key companies which are developing the therapies for Pheochromocytoma. The companies which have their Pheochromocytoma drug candidates in the most advanced stage, i.e. Preregistration include, Pfizer.

 

Pheochromocytoma Pipeline: Phases

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Find out more about the Pheochromocytoma Pipeline Segmentation, Therapeutics Assessment, and Pheochromocytoma Emerging Drugs @ Pheochromocytoma Treatment Landscape

 

Scope of the Pheochromocytoma Pipeline Report

 

  • Coverage- Global

 

  • Pheochromocytoma Companies- Pfizer, Exelixis, Ipsen, Genentech, Astex Pharmaceuticals, Advanced Accelerator Applications, and others.

 

  • Pheochromocytoma Pipeline Therapies- 123I-mIBG (meta-iodobenzylguanidine), Ultratrace Iobenguane (MIBG) I 131, Sunitinib, temsirolimus, vinorelbine ditartrate, isolated perfusion, melphalan, Indium-111 pentetreotide, and others

 

  • Pheochromocytoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration 

 

Dive deep into rich insights for drugs for Pheochromocytoma Pipeline Companies and Therapies, click here @ Pheochromocytoma Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Pheochromocytoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Pheochromocytoma – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Pheochromocytoma Collaboration Deals
  9. Late Stage Products (Preregistration)
  10. Drug name: Company name
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Sunitinib: Pfizer
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. Drug name: Company name
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. Drug name: Company name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Pheochromocytoma Key Companies
  23. Pheochromocytoma Key Products
  24. Pheochromocytoma- Unmet Needs
  25. Pheochromocytoma- Market Drivers and Barriers
  26. Pheochromocytoma- Future Perspectives and Conclusion
  27. Pheochromocytoma Analyst Views
  28. Pheochromocytoma Key Companies
  29. Appendix

 

Got Queries? Find out the related information on Pheochromocytoma Mergers and acquisitions, Pheochromocytoma Licensing Activities @ Pheochromocytoma Recent Trends, and Future Perspectives 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Author

admin

admin